Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial
fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics
(anti-thrombotic potential) in the target population